Ionis to license hep B programme to GSK
GSK is now responsible for all development, regulatory and commercialisation activities and costs.
Read More
Author: Anna Smith
AZ’ triple combo hits endpoint in COPD trial
Breztri Aerosphere – formerly known as PT010 – showed a 52% reduction in exacerbations.
Read More
NICE updates hypertension guideline
The clinical management of hypertension accounts for 12% of visits to primary care and up to £2.1 billion of healthcare expenditure.
Read More
Empliciti combo bags EU approval for multiple myeloma
The approval is based on data from the ELOQUENT-3 trial.
Read More
EU expands approval of Alexion’s Soliris
At 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
